Carrier Activity of Sonicated Small Liposomes Containing Melphalan to Regional Lymph Nodes of Rats

Khato, Juneji; Campo, A A del; Sieber, S. M.

doi:10.1159/000137806

Cited by 31 publications

(5 citation statements)

References 12 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with earlier findings of others, size appeared a crucial factor influencing lymphatic uptake of liposomes [15,16,17,18]. Small liposomes, with a mean size smaller than 0.1 pm, were taken up into the lymphatic capillaries to a high extent, whereas lymphatic uptake clearly declined with an increasing mean liposome size (Table 1).…”

Section: Influence Of Lidosomal Sizesupporting

confidence: 90%

Subcutaneous Administration of Liposomes for Lymphatic Targeting

Oussoren

Storm

1997

Journal of Liposome Research

View full text Add to dashboard Cite

Liposomes have received considerable interest for targeting to regional lymph nodes after S.C. administration. Detailed information on factors influencing lymphatic uptake and lymph node localization of S.C. administered liposomes is, however, not readily available. The present paper provides a short overview of the outcome of recently performed studies on factors potentially affecting lymphatic disposition of liposomes after S.C. injection into rats. An important factor influencing lymphatic disposition was found to be the anatomical site of injection. S.C. injection into the dorsal side of the foot or in the footpad resulted in relatively high uptake (about 40% of the injected dose (%ID)) of small liposomes (mean size about 0.10 pm) from the site of injection compared to uptake from the S.C. injection site at the flank from which uptake was low (c 5 %ID). Liposome size was found to be the most important liposome characteristic influencing lymphatic disposition of S.C. administered liposomes. Small, liposomes (mean size about 0.04 pm) were taken up by the lymphatic system to a relatively high extent (about 74 %ID) compared to large, non-sized liposomes which remained present almost completely at the site of injection. Small liposomes were less efficiently retained by regional lymph nodes than larger liposomes. Liposomal lipid composition did not influence lymphatic disposition significantly with one exception: lymph node localization of liposomes was substantially enhanced by inclusion of phosphatidylserine into the liposomal bilayers. Remarkably, lymphatic uptake and lymph node localization was only slightly affected by distearoylphosphatidylethanolamine-poly(ethyleneg1ycol) (DSPE-PEG') mediated steric stabilization of the liposome surface. Studies designed to elucidate the intranodal fate of liposomes confirmed that liposomes are mainly taken up by lymph node macrophages. Small liposomes may also be taken up 227 Copyright 0 1997 by Marcel Dekker, Inc.

show abstract

Section: Influence Of Lidosomal Sizesupporting

confidence: 90%

Subcutaneous Administration of Liposomes for Lymphatic Targeting

Oussoren

Storm

1997

Journal of Liposome Research

View full text Add to dashboard Cite

show abstract

“…An equivalent effect on the reduction of lymph node metastases was achieved comparing 0.125 mg/kg liposome-melphalan and 1 mg/kg free melphalan. The role of the liposomal size in lymphatic uptake was investigated in a separate study [23] . Melphalan-encapsulated liposomes produced by short (2 – 4 min) periods of sonication resulted in larger liposomes with sizes ≤ 250 nm.…”

Section: Liposome-based Drug Delivery Systemmentioning

confidence: 99%

Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies

Xie

Bagby

Cohen

et al. 2009

Expert Opinion on Drug Delivery

144

121

View full text Add to dashboard Cite

Cancer is the second leading cause of death in the US. Currently, protocols for cancer treatment include surgery to remove diseased and suspect tissues, focused radiation, systemic chemotherapy, immunotherapy and their combinations. With conventional chemotherapy, it is almost impossible to deliver anticancer drugs specifically to the tumor cells without damaging healthy organs or tissues. Over the past several decades, efforts have been made to improve drug delivery technologies that target anticancer drugs specifically to tumor cells. It has been known for over four decades that the lymphatics are the first site of metastasis for most solid cancers; however, few efforts have been made to localize chemotherapies to lymphatic tissues. Trials of several systemic targeted drug delivery systems based on nanoparticles containing chemotherapeutic agents (e.g., liposomal doxorubicin) have shown similar antitumor activity but better patient tolerance compared with conventional formulations. Animal studies have demonstrated that nanoparticles made of natural or synthetic polymers and liposomal carriers have higher accumulation in the lymph nodes and surrounding lymphatics compared to conventional intravenous therapies. This combination has the potential to both reduce nonspecific organ toxicities and increase the chemotherapeutic dose to the most likely sites of locoregional cancer metastasis.

show abstract

“…Jackson5 and Khato e t a1. 6 have demonstrated delivery of liposome-encapsulated compounds to regional lymph nodes following intramuscular and subcutaneous injection, and observe that liposome size can be an important variable. Control of local and systemic drug levels may also be possible if release of drug from its carrier can be reliably modulated.…”

mentioning

confidence: 99%